

LINCOLN HOUSE, B1H, SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 050.  
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED ON 31.03.2012

PART - I	PARTICULARS	QUARTER ENDED				YEAR ENDED				STANDARD			
		31.03.2012 (Un-Audited)	31.12.2011 (Un-Audited)	31.03.2011 (Un-Audited)	31.03.2011 (Audited)	31.03.2012 (Un-Audited)	31.03.2011 (Audited)	31.03.2012 (Un-Audited)	31.03.2011 (Un-Audited)	31.03.2012 (Un-Audited)	31.03.2011 (Un-Audited)	31.03.2011 (Un-Audited)	31.03.2012 (Un-Audited)
1	Income from operations	3998.89	5452.91	6223.02	18990.92	17689.82	3954.16	5382.15	5504.06	17435.48	18624.81		
(a)	Net Sales/Income from operation (Net of excise duty)	229.29	19.15	239.28	348.26	289.45	224.79	19.15	228.83	335.78	278.01		
(b)	Other operating income	4228.18	5472.56	6462.30	19038.38	17650.38	4789.55	5371.30	5792.89	17892.27	18692.91		
	Total Income from operations (net)	1024.89	723.01	1135.96	3704.89	3742.58	1924.79	723.01	1135.96	3640.18	3742.58		
2	Expenses												
(a)	Cost of materials consumed	1927.06	2601.31	4060.52	8057.08	8097.29	1927.06	2494.95	3227.72	7155.78	6927.73		
(b)	Purchases of stock-in-trade	-68.18	283.32	-478.08	490.21	-135.28	-68.18	283.32	-97.44	390.35	-30.84		
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	436.24	413.60	389.92	1672.21	145.28	409.46	413.60	389.32	1581.35	1444.88		
(d)	Employee benefits expense	69.58	44.84	80.95	193.58	166.88	61.34	44.84	60.75	198.64	166.88		
(e)	Depreciation and amortisation expense	583.89	1178.54	1180.16	3523.75	3680.57	557.68	1184.85	1182.01	3442.32	3549.14		
(f)	Other expenses	3870.48	5224.02	6349.43	17637.52	16877.31	3911.74	5123.85	5621.97	14589.13	15844.15		
	Total expenses	257.70	248.03	112.87	1401.36	1080.06	267.21	247.72	111.02	1399.13	1058.75		
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1)-(2)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
4	Other Income	257.70	248.03	112.87	1401.36	1080.06	267.21	247.72	111.02	1399.13	1058.75		
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items* 4)	183.32	181.58	159.19	674.36	462.48	174.15	181.58	159.12	659.90	461.67		
6	Finance costs	74.38	66.48	-46.32	725.56	617.58	93.05	66.18	40.10	746.23	597.08		
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items* 6)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
8	Exceptional items	74.38	66.48	-46.32	725.56	617.58	93.05	66.18	40.10	746.23	597.08		
9	Profit/(Loss) from ordinary activities before tax (7 + 8)	74.38	66.48	-46.32	725.56	617.58	93.05	66.18	40.10	746.23	597.08		
10	Tax expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
11	Net Profit/(Loss) from ordinary activities after tax (9 - 10)	74.38	66.48	-46.32	725.56	617.58	93.05	66.18	40.10	746.23	597.08		
12	Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
13	Net Profit/(Loss) for the period (11 + 12)	74.38	66.48	-46.32	725.56	617.58	93.05	66.18	40.10	746.23	597.08		
14	Share of profit/(loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
15	Minority interest	60.66	51.93	-93.04	501.54	416.54	76.38	44.72	94.00	451.11	408.13		
16	Net Profit/(Loss) after taxes, minority interest and shares of profit/(loss) of associates [(13 + 14 + 15)] *	134.72	118.41	-139.36	1227.10	1031.04	172.56	116.90	134.00	1295.34	1006.21		
17	Pre-liquidation share capital of face value Rs. 100/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08		
18	Reserve excluding Revaluation Reserves as per balance sheet of previous a/c. year	0.37	0.35	0.00	3.07	4.22	0.47	0.31	0.00	3.01	4.14		
19	191. (a) Basic and diluted EPS before Extraordinary items (16 - 17) each and (18) prior adjustment (Net Annualised)	0.37	0.35	0.00	3.07	4.22	0.47	0.31	0.00	3.01	4.14		
191. (b) Basic and diluted EPS after Extraordinary items (16 - 17) each and (18) prior adjustment (Net Annualised)	0.37	0.35	0.00	3.07	4.22	0.47	0.31	0.00	3.01	4.14			

NOTES:-  
1. The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 15.05.2012.  
2. Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.  
3. The Company has one VIOS Family Zulfic Healthcare Limited as at 31.03.2012.  
4. M/s Lincoln Pharmaceutical Ltd. has become subsidiary of the Company w.e.f. 06.12.11.  
Place : Ahmedabad  
Date : 15.05.2012

For LINCOLN PHARMACEUTICALS LIMITED  
(M) Mehendra G. Patel  
Managing Director

